Pegamotecan

Drug Profile

Pegamotecan

Alternative Names: Camptothecin macrogol; EZ-246; PEG-camptothecin; Polyethylene glycol camptothecin; Prothecan

Latest Information Update: 08 Feb 2005

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Enzon Pharmaceuticals
  • Class Alkaloids; Antineoplastics; Camptothecins
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Gastric cancer; Non-small cell lung cancer; Pancreatic cancer; Small cell lung cancer

Most Recent Events

  • 08 Feb 2005 Discontinued - Phase-II for Gastric cancer in USA (Infusion)
  • 28 Jul 2003 Discontinued - Phase-II for Non-small cell lung cancer in USA (Infusion)
  • 28 Jul 2003 Discontinued - Phase-II for Pancreatic cancer in USA (Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top